Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected or histological/cytological diagnosis of Non-Small Cell Lung Cancer (NSCLC), Stage IB (≥4 cm per CT) or Stage IIA or IIB, amenable to surgical resection~* Must be deemed a surgical candidate~* Tumors ≥2 cm in maximum diameter without radiographic, bronchoscopic or pathologic evidence of nodal metastases are eligible for biopsy~* Fresh tissue biopsy material must be available for genomics analysis prior to initiating dasatinib therapy~* Age ≥18 years~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2~* No prior chemotherapy, immunotherapy, radiation therapy or biologic/targeted therapy for any malignancy~* Adequate Organ Function:~  * Total bilirubin \<institutional upper limit normal (ULN)~ * Hepatic enzymes (AST, ALT) ≤2.5x institutional ULN~ * Serum creatinine \<1.5x institutional ULN~ * Hemoglobin ≥9 gm/dL~ * Neutrophil count (ANC or AGC) ≥1500 per μL~ * Platelets ≥100,000 per μL~ * Prothrombin time (PT)/a partial thromboplastin time (PTT) ≤1.5x control~* No other serious medical or psychiatric illness~* Ability to take oral medication (dasatinib must be swallowed whole)~* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test preferably within 72 hours and no later than 7 days, prior to the start of study drug administration~* Both sexually active males and females of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped~* Signed written informed consent including Health Insurance Portability and Accountability Act (HIPAA) according to institutional guidelines~Exclusion Criteria:~* Previous or concomitant malignancy in the past 2 years other than curatively treated carcinoma in situ of the cervix, basal cell or squamous cell carcinoma of the skin~* Prior dasatinib therapy~* Evidence of pleural or pericardial effusion of any grade~* Cardiac Symptoms:~  * Uncontrolled angina, congestive heart failure (CHF), or myocardial infarction (MI) within 6 months~ * Diagnosed congenital long QT syndrome~ * Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes)~ * Prolonged QT corrected (QTc) interval on pre-entry EKG (\>450 msec)~ * Uncontrolled hypertension defined as \>160/90 on a regimen of antihypertensive therapy~* Subjects with hypokalemia or hypomagnesaemia if it cannot be corrected~* History of diagnosed congenital acquired bleeding disorders (e.g., von Willebrand's disease)~* Ongoing or recent (≤3 months) significant (≥grade 3) gastrointestinal bleeding~* Concomitant Medications:~  * Drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (Patients must discontinue drug 7 days prior to starting dasatinib)~    \*\*quinidine, procainamide, disopyramide, amiodarone, sotalol, ibutilide, dofetilide, erythromycin, clarithromycin, chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine~ * Current therapeutic dose heparin or coumadin therapy~ * St. John's Wort and all herbal supplements must be stopped while on dasatinib~ * IV bisphosphonates will be withheld for 2 weeks prior and 6 weeks after dasatinib administration due to risk of hypocalcaemia~* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness~* Pregnant or breastfeeding~* Active or uncontrolled infection requiring intravenous antibiotics~* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of dasatinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)~* Patients who have received investigational drugs ≤4 weeks prior to starting study drug and/or who have not recovered from side effects of such therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Neoadjuvant dasatinib is to be administered as an oral dose of 70 mg PO twice daily on a continuous basis for 3 weeks prior to surgery. Patients will begin adjuvant dasatinib (70 mg PO twice daily) between 4-6 weeks after standard adjuvant therapy is complete or 4-8 weeks after surgery for those patients that do not receive adjuvant chemotherapy. Adjuvant dasatinib will be given on a continuous basis for up to 3 months after adjuvant chemotherapy or after surgery if no adjuvant chemotherapy is given.

Based on this trial design, predict the completion outcome and termination type (if applicable).